FDA orders GLP-1 drug makers to add eye warnings
The U.S. Food and Drug Administration is requiring labels on weight-loss drugs like Ozempic and Wegovy about a rare eye condition.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
What happened
The U.S. Food and Drug Administration warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes called an "eye stroke." The agency then ordered makers of GLP-1 drugs, including Ozempic and Wegovy, to add warnings about the condition, known as NAION. The condition can lead to blindness.
Why it matters
The condition can lead to blindness.
Timeline
- Nov 9, 10:56 AM ET: The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes called an "eye stroke."
- Nov 10, 1:16 PM ET: The FDA ordered makers of Ozempic, Wegovy and other weight-loss drugs to add warnings about the condition, known as NAION.
Coverage
- Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness (BBC)
- FDA orders GLP-1s add eye risk to labels (fiercepharma.com)
- GLP-1s are given an FDA warning for rare eye condition risk (statnews.com)
- Pharmalittle: We're reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more (statnews.com)
- FDA warns GLP-1 drugs carry potential risk of rare eye condition (statnews.com)
More from Health
- WHO says cholera deaths top 3,000 this year
- Georgia health officials confirm three more measles cases
- Hospitals write off $132 billion as AI fails to lift finances
- Oura agrees to buy AI firm Counsel Health for $625 million
- Pennsylvania measles cases rise among pregnant women and adults
- Ohio State study links wastewater bacteria to community health